Skip to content

Toceranib (Palladia) Tyrosine Kinase Inhibitor for MCT

A heartwarming moment of a cat cuddling a dog on green grass outdoors.

What Palladia Is and Why It Was a Turning Point

Toceranib phosphate, marketed under the brand name Palladia by Zoetis, was the first cancer drug ever developed and FDA-approved specifically for dogs. The 2009 approval was a turning point: until then, veterinary oncologists treated dogs almost entirely with chemotherapy agents originally designed for humans. Palladia changed that by offering a canine-specific, orally administered option for one of the most common skin cancers in dogs.

The toceranib palladia mct indication centers on recurrent or non-resectable Patnaik grade II or III cutaneous mast cell tumors, with or without regional lymph node involvement. In practice, board-certified veterinary medical oncologists (DACVIM-Oncology) also use it off-label for several other cancers that share the same molecular vulnerabilities, including anal sac adenocarcinoma, thyroid carcinoma, and head and neck squamous cell carcinoma.

For adopters of dogs with a mast cell tumor history, Palladia is one of the reasons modern oncology can offer a genuine quality-of-life arc rather than a short course of injectable chemotherapy. It is an oral pill given at home, often for many months, which fundamentally changes the daily experience of cancer care.

How Tyrosine Kinase Inhibitors Work

Tyrosine kinases are signaling switches inside cells. When mutated or overexpressed, they tell tumor cells to grow, survive, and recruit new blood supply. Palladia blocks several of these switches at once. Its primary targets are KIT (the receptor that drives many mast cell tumors), VEGFR (which controls tumor blood vessel formation), and PDGFR (which supports tumor stroma and growth).

By inhibiting KIT, Palladia interrupts the survival signal that mutated mast cells depend on. By inhibiting VEGFR and PDGFR, it starves the tumor of new vasculature. This dual mechanism explains why the drug is effective both in tumors with confirmed KIT mutations and in some tumors driven primarily by angiogenesis.

The KIT Mutation Story

Roughly 15 to 30 percent of canine mast cell tumors carry an internal tandem duplication mutation in exon 11 of the c-KIT gene. These KIT-mutated tumors are the patients who respond best to Palladia. KIT mutation testing on biopsy tissue is now routine for high-grade or recurrent tumors and is typically requested by the oncologist when biopsy material is submitted to the pathologist (DACVP).

Dogs with confirmed exon 11 ITD mutations often experience durable responses; dogs without the mutation may still respond, but at lower rates. The mutation result guides decision-making about whether to use Palladia first or as a later-line option. For more on how mast cell tumors are graded and staged, the Kiupel two-tier versus Patnaik three-tier MCT grading framework explains the pathology language oncologists rely on.

When Palladia Is Considered

Palladia is most commonly recommended in three scenarios. The first is recurrent or non-resectable cutaneous mast cell tumors where surgery cannot achieve clean margins. The second is mast cell tumors that have spread to regional lymph nodes but have not yet metastasized to distant organs. The third is adjuvant use after surgical removal of high-grade tumors to reduce the chance of recurrence, particularly when histopathology shows high-risk features such as elevated mitotic count, multinucleated cells, or bizarre nuclei.

Off-label use in apocrine gland anal sac adenocarcinoma is now well documented and often produces meaningful tumor shrinkage and clinical benefit, particularly for hypercalcemia of malignancy associated with these tumors. Thyroid carcinoma and head and neck squamous cell carcinoma are additional contexts where DACVIM-Oncology specialists may consider Palladia.

How Treatment Is Started and Monitored

Palladia is given orally on a Monday-Wednesday-Friday or every-other-day schedule. The exact dosing is determined by the medical oncologist based on body weight, body condition, tumor type, and individual tolerance. We do not provide milligram-per-kilogram dosing here because tyrosine kinase inhibitor therapy is highly individualized and titrated to lab values, side effects, and response.

Before starting therapy, your oncologist will obtain a complete blood count, serum chemistry, and a urine protein-to-creatinine ratio. Repeat bloodwork is typically performed every two to four weeks during the first months of therapy and then less frequently if the dog is stable. The team is watching for neutropenia, anemia, elevated liver enzymes, kidney changes, and protein in the urine.

Common Side Effects and Dose Modifications

Diarrhea is the most common Palladia side effect, often appearing in the first two weeks. It usually responds to dose reduction, brief treatment breaks, and supportive care including Cerenia or similar antiemetics. Anorexia and lameness are also common in early therapy. Less common but important side effects include neutropenia, proteinuria, hypertension, and bleeding from a gastrointestinal lesion.

When side effects emerge, the oncologist may pause Palladia for a few days, restart at a lower dose, or change the dosing schedule. Many dogs ultimately settle at a slightly lower dose that they tolerate well for many months. The goal is sustained control of the tumor with quality of life intact, not the highest tolerable dose.

Combining Palladia With Other Therapies

Modern mast cell tumor management is multimodal. Palladia is often combined with prednisone, antihistamines, and gastroprotectants because mast cell tumors release histamine and can cause gastric ulceration. For some patients, a low dose of vinblastine or lomustine is added under careful monitoring. For non-resectable or refractory tumors, your oncologist may pair Palladia with Stelfonta intratumoral tigilanol mesylate for direct tumor necrosis, or with stereotactic or conventional radiation therapy for local control.

For dogs whose mast cell tumors are not surgically removable and where systemic disease has been ruled out, electrochemotherapy with cisplatin and bleomycin pulse represents another option that can be combined with or sequenced after Palladia in selected referral practices.

What Response Looks Like and What to Expect

Response on Palladia is judged by tumor measurements, lymph node size, and overall clinical status. Some dogs see partial responses within four to eight weeks, while others show stable disease for many months. A subset of dogs with KIT-mutated tumors experience durable complete responses. The published median time to tumor progression varies by study and tumor type, but the published survival data for high-grade mast cell tumors treated with surgery plus Palladia have been encouraging compared with surgery alone.

Prognosis remains highly individual. Some dogs live one to two years or longer with well-managed Palladia therapy; others progress more quickly. The medical oncologist will communicate realistic median survival time ranges from the peer-reviewed literature without predicting your specific dog’s outcome.

Cost and Access

Palladia typically runs around four hundred to eight hundred dollars per month depending on the dog’s size and dose, and the dispensing pharmacy. Costs vary by region, dose strength, and how often monitoring labs are required. Most dogs continue on Palladia for many months, so families plan for ongoing expense rather than a fixed treatment course.

Geographic access is a real consideration. Board-certified veterinary medical oncologists are concentrated in major referral centers and teaching hospitals. If a DACVIM-Oncology specialist is not available in your region, your primary veterinarian can often consult with a specialist via telemedicine, prescribe Palladia following an initial referral, and manage day-to-day monitoring locally. Cancer-care grants such as Magic Bullet Fund, Brown Dog Foundation, and the Pet Fund occasionally help families with chronic oral chemotherapy costs; eligibility is limited but worth exploring.

Adopting a Dog With a Mast Cell Tumor History

Adopters frequently take on dogs who have had a mast cell tumor removed in the past or who are on long-term Palladia. Realistic, informed adopters with a clear plan for follow-up imaging, oncologist visits, and side effect monitoring provide excellent homes. A previous mast cell tumor diagnosis is not a dealbreaker, especially for low-grade tumors with clean surgical margins. Read more about understanding the disease in our mast cell tumors in dogs overview and the related dog mast cell tumor guide.

If you are considering adopting a dog already on Palladia, ask the rescue or foster for the most recent bloodwork, the prescribing oncologist’s contact, and the monitoring schedule. Continuity of care matters more than which clinic provides it.

Frequently Asked Questions

Is Palladia chemotherapy?

Palladia is classified as a targeted therapy rather than traditional cytotoxic chemotherapy. It works by blocking specific tyrosine kinase receptors involved in cancer growth and blood supply, rather than killing all rapidly dividing cells. Side effects are typically milder than injectable chemotherapy, although they are still real and require monitoring.

How long do dogs stay on Palladia?

Many dogs stay on Palladia for many months or longer when the tumor is controlled and side effects are manageable. The oncologist re-evaluates at every monitoring visit and adjusts the dose or schedule based on response and tolerability. Treatment continues as long as the dog has good quality of life and the cancer is responding.

Can my dog be around children while on Palladia?

Palladia tablets should be handled with care. Wear gloves when administering, do not crush or split the tablets unless directed, and store securely away from children and other pets. Wash hands after handling. Pregnant or nursing humans should not handle the medication. Your veterinary team will review household precautions at the start of therapy.

Will my dog lose hair on Palladia?

Hair loss is uncommon with Palladia compared with traditional chemotherapy. Some dogs develop coat color changes or thinning at the application sites for blood draws, but generalized alopecia is not typical. Skin changes and depigmentation around the nose or footpads can occur in a minority of patients.

Does Palladia cure mast cell tumors?

Palladia is rarely curative on its own. It is most often used to control recurrent, high-grade, or non-resectable disease and to delay progression. Cure language in veterinary oncology is generally avoided. The realistic frame is sustained disease control and quality of life. Discuss expected median survival times from peer-reviewed literature with your DACVIM-Oncology specialist; outcomes vary widely by tumor grade, KIT mutation status, and individual response.

Ready to adopt?

Find your perfect companion from shelters and rescues near you.

Browse Adoptable Pets

Related articles

Why Does My Chinchilla Nibble Me?
Pet Care

Why Does My Chinchilla Nibble Me?

Wondering why does my chinchilla nibble me? Learn what gentle nibbling means, from grooming and affection to attention-seeking, and how to respond kindly.

Why Does My Chinchilla Rub His Chin?
Pet Care

Why Does My Chinchilla Rub His Chin?

Wondering why does my chinchilla rub his chin? Learn about scent marking, territory, and the rare dental signs that mean it is time to call an exotics vet.

Why Does My Chinchilla Cough?
Pet Care

Why Does My Chinchilla Cough?

Worried why does my chinchilla cough? Learn the dust, respiratory, and dental causes of coughing and exactly when to call an exotics vet right away.